AI Image
Retatrutide beats Ozempic on weight loss, blood sugar control
USA Today • • business
Key Points:
- Eli Lilly's experimental GLP-1 drug retatrutide demonstrated superior blood sugar control and weight loss compared to Novo Nordisk's Ozempic in an 80-week study involving adults with Type 2 diabetes.
- Participants on retatrutide lost more than twice the weight of those on Ozempic, with average weight loss of 44.3 pounds (9 mg dose) and 47.4 pounds (12 mg dose) versus 20.9 pounds for Ozempic's 2 mg dose.
- Retatrutide users lowered their A1C levels by an average of 2.2%, compared to 1.8% for Ozempic users, but experienced more stomach-related side effects and higher discontinuation rates (7.9% vs. 2.7%).
- Novo Nordisk emphasized that Ozempic's benefits extend beyond weight loss, highlighting its proven cardiovascular, kidney, and liver protection, established safety profile, and widespread use by over 28 million people.
- Lilly currently markets weight-loss drug Zepbound and diabetes medication Mounjaro and plans to seek FDA approval for retatrutide by March 2027.
